Recent Advances in Targeting the Ionotropic Glutamate Receptors in Treating Schizophrenia

Author(s): Robert E. McCullumsmith, John Hammond, Adam Funk, James H. Meador-Woodruff.

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 8 , 2012

Become EABM
Become Reviewer

Abstract:

The treatment of schizophrenia has been focused on modulation of dopamine receptors for over 50 years. Recent developments have implicated other neurotransmitter systems in the pathophysiology of this illness. The discovery and characterization of glutamate receptors and their roles in the brain has lead to novel approaches for the treatment of schizophrenia. In this article, we review drugs that modulate ionotropic gluamate receptors and discuss their efficacy for the treatment of this often debilitating severe mental illness.

Keywords: Schizophrenia, glutamate, NMDA, AMPA, kainate, glycine, D-serine, lamotrigene, dopamine receptors, neurotransmitter systems, athophysiology, glutamate receptors, novel approaches, ionotropic gluamate receptors

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 8
Year: 2012
Page: [1535 - 1542]
Pages: 8
DOI: 10.2174/138920112800784899
Price: $65

Article Metrics

PDF: 4